Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.
CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.
Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.
What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.
Ranjith Gopinathan, programme manager, life sciences and healthcare practice at Frost & Sullivan, discusses pharmaceutical groups Merck and Pfizer ahead of their quarterly results.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.
A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.
Doug Oberhelman, Caterpillar chairman & CEO, weighs in on the manufacturer's fiscal second quarter of EPS $1.69 ex-items on revenues of $14.15 billion.
The big large-scale combinations are not right for Lilly right now, says John Lechleiter, Eli Lilly CEO, discussing how the company plans to expand its pharmaceutical footprint through acquiring smaller companies. Also Lechleiter weighs in on growing its animal health care business.
John Lechleiter, Eli Lilly CEO, breaks down the pharmaceutical giant's quarterly results. And Lechleiter weighs in on the benefits of investing in R&D.
Raghuram Selvaraju, Head of Healthcare Equity Research at Aegis Capital, outlines the factors that weighed on GlaxoSmithKline's second quarter earnings.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
Bill Ackman fired his latest shot at Herbalife Tuesday, but the company's stock mostly rose during the investor's presentation.
Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.
FedEx's indictment for shipping packages from illegal online pharmacies isn't hurting shares, which makes sense to one analyst.
FedEx was indicted for shipping packages from illegal online pharmacies despite repeated warnings from U.S. drug enforcement officials.
Surani Fernando, assistant editor at Biopharm Insight, says the market sees the latest Abbvie's takeover bid for Shire as fair and that the announcement of a merger should soon be made.
Lars Sorensen, Novo Nordisk CEO, explains why the Affordable Care Act isn't affordable for people with diabetes.
Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.